Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6203Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Craig Wallington-Gates | en |
| dc.date.accessioned | 2024-08-08T02:57:10Z | - |
| dc.date.accessioned | 2024-08-08T03:36:03Z | - |
| dc.date.available | 2024-08-08T02:57:10Z | - |
| dc.date.available | 2024-08-08T03:36:03Z | - |
| dc.date.issued | 2021 | - |
| dc.identifier.citation | Resistance to Targeted Anti-Cancer Therapeutics, 2021 | en |
| dc.identifier.isbn | 9783030734398 | - |
| dc.identifier.isbn | 9783030734404 | - |
| dc.identifier.uri | https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6203 | - |
| dc.language.iso | en | en |
| dc.publisher | Springer International Publishing | en |
| dc.title | Mechanisms Driving Resistance to Proteasome Inhibitors Bortezomib, Carfilzomib, and Ixazomib in Multiple Myeloma | en |
| dc.type | Book chapter | en |
| dc.identifier.doi | 10.1007/978-3-030-73440-4_4 | - |
| dc.rights.holder | Craig Wallington-Gates | en |
| dc.identifier.journaltitle | Resistance to Targeted Anti-Cancer Therapeutics | - |
| dc.identifier.external | 98208117 | - |
| item.cerifentitytype | Publications | - |
| item.fulltext | No Fulltext | - |
| item.languageiso639-1 | en | - |
| item.openairetype | Book chapter | - |
| item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
| item.grantfulltext | none | - |
| Appears in Sites: | Queensland Health Publications Sunshine Coast HHS Publications | |
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.